Comparative Pharmacology
Head-to-head clinical analysis: DIFLUNISAL versus FLURBIPROFEN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFLUNISAL versus FLURBIPROFEN SODIUM.
DIFLUNISAL vs FLURBIPROFEN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, thereby decreasing prostaglandin synthesis, which mediates inflammation, pain, and fever.
500 mg to 1000 mg orally initially, then 250 mg to 500 mg every 8 to 12 hours. Maximum daily dose: 1500 mg.
50 mg orally every 4 to 6 hours as needed; maximum 300 mg per day.
None Documented
None Documented
8-12 hours (prolonged in renal impairment; clinical context: permits twice-daily dosing)
Clinical Note
moderateDiflunisal + Gatifloxacin
"Diflunisal may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateDiflunisal + Rosoxacin
"Diflunisal may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateDiflunisal + Levofloxacin
"Diflunisal may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateDiflunisal + Trovafloxacin
"Diflunisal may increase the neuroexcitatory activities of Trovafloxacin."
3-4 hours; in elderly or hepatic impairment may extend to 5-6 hours.
Renal (90% as glucuronide conjugates, <5% unchanged); biliary/fecal (<10%)
Renal: 70% as conjugates (glucuronide) and unchanged drug (<1%); biliary/fecal: minimal.
Category C
Category D/X
NSAID
NSAID